Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2

Conditions

Breast Neoplasms 107Carcinoma, Renal Cell 74Neoplasm Metastasis 48Neoplasms 37Neuroendocrine Tumors 35Kidney Neoplasms 27Recurrence 19Tuberous Sclerosis 18Carcinoma, Non-Small-Cell Lung 17Prostatic Neoplasms 16Triple Negative Breast Neoplasms 15Lymphoma 15Lymphoma, Mantle-Cell 14Lymphoma, Large B-Cell, Diffuse 14Head and Neck Neoplasms 14Glioblastoma 14Carcinoma, Hepatocellular 14Colorectal Neoplasms 13Stomach Neoplasms 12Lung Neoplasms 12Leukemia, Lymphocytic, Chronic, B-Cell 12Hodgkin Disease 12Brain Neoplasms 12Sarcoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Pancreatic Neoplasms 11Glioma 11Waldenstrom Macroglobulinemia 10Lymphoma, Follicular 10Carcinoma, Neuroendocrine 10

Interventions

Rituximab 112Cyclophosphamide 103fludarabine 61Doxorubicin 33Vincristine 31Etoposide 31Prednisone 30Lenalidomide 24ibrutinib 22fludarabine phosphate 21Immunotherapy, Adoptive 19Bendamustine Hydrochloride 19obinutuzumab 18Cytarabine 18pembrolizumab 16Magnetic Resonance Spectroscopy 16Bortezomib 14Specimen Handling 13Dexamethasone 13polatuzumab vedotin 12CT-P10 12venetoclax 11pirtobrutinib 11Gemcitabine 11Carboplatin 11glofitamab 10zanubrutinib 9Nivolumab 9Mycophenolic Acid 9Melphalan 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × Everolimus × Clear all
NCT04305444 2025-01-08

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Zhejiang DTRM Biopharma

Phase 2 Terminated
55 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01665768 2021-10-26

Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
56 enrolled 10 charts
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT00702052 2021-05-25

PILLAR-1

Novartis

Phase 2 Completed
58 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT00790036 2017-07-12

PILLAR2

Novartis

Phase 3 Completed
742 enrolled 10 charts
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡